Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5306-5314

  Roch, Mélanie ^a,b,c,d,e   Clair, Perrine ^e   Renzoni, Adriana ^f   Reverdy, Marie Elisabeth ^e   Dauwalder, Olivier ^a,b,c,d,e   Bes, Michèle ^a,b,c,d,e   Martra, Annie ^e   Freydière, Anne Marie ^e   Laurent, Frédéric ^a,b,c,d,e   Reix, Philippe ^e   Dumitrescu, Oana ^a,b,c,d,e   Vandenesch, François ^a,b,c,d,e  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CNRS   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CEFTRIAXONE; DAPTOMYCIN; IMIPENEM; VANCOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG EFFICACY; GENE DISRUPTION; IN VITRO STUDY; LONG TERM EXPOSURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; R FACTOR; TRANSMISSION ELECTRON MICROSCOPY; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; ULTRASTRUCTURE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFTAZIDIME; CEFTRIAXONE; DRUG RESISTANCE, BACTERIAL; IMIPENEM; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, TRANSMISSION; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84906089525     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02574-14     Document Type: Article

References (38)

1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC, Hospital J. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-146. http://dx.doi.org/10.1093/jac/40.1.135.
2. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673. http://dx.doi.org/10.1016/S0140-6736(97)07324-8. (Pubitemid 28036828)
3. Appelbaum PC. 2007. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 30:398-408. http://dx.doi.org/10.1016/j.ijantimicag.2007.07.011. (Pubitemid 47498971)
4. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139. http://dx.doi.org/10.1128/CMR.00042-09.
5. Liu C, Chambers HF. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47: 3040-3045. http://dx.doi.org/10.1128/AAC.47.10.3040-3045.2003. (Pubitemid 37229554)
6. Bobin-Dubreux S, Reverdy M-E, Nervi C, Rougier M. 2001. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. Antimicrob. Agents Chemother. 45:349-352. http://dx.doi.org/10.1128/AAC.45.1. 349-352.2001. (Pubitemid 32039145)
7. Tenover FC, Moellering RC. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215. http://dx.doi.org/10.1086/513203. (Pubitemid 46651246)
8. Moore MR, Chambers HF. 2003. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47:1262-1266. http://dx.doi.org/10.1128/AAC.47.4.1262-1266.2003. (Pubitemid 36368583)
9. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC. 2004. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38:1700-1705. http://dx.doi.org/10.1086/ 421092. (Pubitemid 38781661)
10. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, Tenover FC. 2003. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36:429-439. http://dx.doi.org/10.1086/346207. (Pubitemid 36241308)
11. Katayama Y, Murakami-Kuroda H, Cui L, Hiramatsu K. 2009. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. Antimicrob. Agents Chemother. 53:3190-3196. http://dx.doi.org/10.1128/AAC.00834- 08.
12. Cafiso V, Bertuccio T, Spina D, Campanile F, Bongiorno D, Santagati M, Sciacca A, Sciuto C, Stefani S. 2010. Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 29:1277-1285. http://dx.doi.org/10.1007/s10096- 010-1000-5.
13. Filleron A, Chiron R, Reverdy M-E, Jean-Pierre H, Dumitrescu O, Aleyrangues L, Counil F, Jumas-Bilak E, Marchandin H. 2011. Staphylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients. J. Cyst. Fibros. 10:377-382. http://dx.doi.org/10.1016/j.jcf.2011.05. 001.
14. Poncelet M. 2011. Caractéristiques cliniques des patients pédiatriques atteints de mucoviscidose colonisés par Staphylococcus aureus méthicilline-résistant de sensibilité hétérogène aux glycopeptides. M.D. thesis. University of Lyon, Lyon, France.
15. Denis O, Nonhoff C, Byl B, Knoop C, Bobin-Dubreux S, Struelens MJ. 2002. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J. Antimicrob. Chemother. 50:383-391. http://dx.doi.org/10.1093/jac/dkf142.
16. Wootton M, Howe R, Hillman R, Walsh TR, Bennett PM, MacGowan AP. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403. http://dx.doi.org/10.1093/jac/47.4.399. (Pubitemid 32303403)
17. Monecke S, Luedicke C, Slickers P, Ehricht R. 2009. Molecular epidemiology of Staphylococcus aureus in asymptomatic carriers. Eur. J. Clin. Microbiol. Infect. Dis. 28:1159-1165. http://dx.doi.org/10.1007/s10096-009-0752- 2.
18. Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann A-C. 2012. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 56:5845-5851. http://dx.doi.org/10.1128/AAC.01139-12.
19. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic Local Alignment Search Tool. J. Mol. Biol. 215:403-410.
20. Renzoni A, Kelley WL, Barras C, Monod A, Huggler E, François P, Schrenzel J, Studer R, Vaudaux P, Lew DP. 2009. Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 53:903-911. http://dx.doi.org/10.1128/AAC.01287-08.
21. Cervera C, Castañeda X, Pericas JM, Del Río A, de la Maria CG, Mestres C, Falces C, Marco F, Moreno A, Miró JM. 2011. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci. Int. J. Antimicrob. Agents 38:365-370. http://dx.doi.org/10.1016/j.ijantimicag. 2010.11.038.
22. Boyle-Vavra S, Berke SK, Lee JC, Daum RS. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-277. http://dx.doi.org/10.1128/AAC.44.2. 272-277.2000. (Pubitemid 30060718)
23. Rodriguez C, Agudelo M, Zuluaga AF, Vesga O. 2012. Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model. Antimicrob. Agents Chemother. 56:243-247. http://dx.doi.org/10.1128/AAC.05129-11.
24. Errecalde L, Ceriana P, Gagetti P, Erbín M, Duarte A, Rolon M, Cuatz D, Corso A, Kaufman S. 2013. Primer aislamiento en Argentina de Staphylococcus aureus intermedia a la vancomicina y no sensibilidad a la daptomicina. Rev. Argent. Microbiol. 45:99-103.
25. Hiramatsu K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155. http://dx.doi.org/10.1016/S1473-3099(01)00091-3. (Pubitemid 33586048)
26. Hanaki H, Daum RS, Labischinski H, Hiramatsu K. 1998. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 42:199-209. http://dx.doi.org/10.1093/jac/42.2.199. (Pubitemid 28393588)
27. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. 2000. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44:2276-2285. http://dx.doi.org/10.1128/AAC.44.9.2276-2285. 2000. (Pubitemid 30650868)
28. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, Gemmell CG, Kim MN, Ploy MC, El-Solh N, Ferraz V, Hiramatsu K. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14. http://dx.doi.org/10.1128/JCM.41.1.5-14.2003. (Pubitemid 36098547)
29. Hanaki H, Yamaguchi Y, Yanagisawa C, Uehara K, Matsui H, Yamaguchi Y, Hososaka Y, Barada K, Sakai F, Itabashi Y, Ikeda S, Atsuda K, Tanaka H, Inamatsu T, Nagayama A, Sunakawa K. 2005. Investigation of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR). J. Infect. Chemother. 11:104-106. http://dx.doi.org/10.1007/s10156-004-0371-X. (Pubitemid 40645885)
30. McAleese F, Wu SW, Sieradzki K, Dunman P, Murphy E, Projan S, Tomasz A. 2006. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate-S. aureus-type resistance to vancomycin. J. Bacteriol. 188:1120-1133. http://dx.doi.org/10. 1128/JB.188.3.1120-1133.2006. (Pubitemid 43146428)
31. Utaida S, Dunman PM, Macapagal D, Murphy E, Projan SJ, Singh VK, Jayaswal RK, Wilkinson BJ. 2003. Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology 149:2719-2732. http://dx.doi.org/10. 1099/mic.0.26426-0. (Pubitemid 37279247)
32. Yin S, Daum RS, Boyle-Vavra S. 2006. VraSR two-component regulatory system and its role in induction of pbp2 and vraSR expression by cell wall antimicrobials in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:336-343. http://dx.doi.org/10.1128/AAC.50.1.336-343.2006. (Pubitemid 43042941)
33. Jousselin A, Kelley WL, Barras C, Lew DP, Renzoni A. 2013. The Staphylococcus aureus thiol/oxidative stress global regulator Spx controls trfA, a gene implicated in cell wall antibiotic resistance. Antimicrob. Agents Chemother. 57:3283-3292. http://dx.doi.org/10.1128/AAC.00220-13.
34. Kock H, Gerth U, Hecker M. 2004. MurAA, catalysing the first committed step in peptidoglycan biosynthesis, is a target of Clp-dependent proteolysis in Bacillus subtilis. Mol. Microbiol. 51:1087-1102. http://dx.doi.org/10.1046/j. 1365-2958.2003.03875.x. (Pubitemid 38270801)
35. Moise PA, North D, Steenbergen JN, Sakoulas G. 2009. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 9:617-624. http://dx.doi.org/10.1016/S1473- 3099(09)70200-2.
36. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585. http://dx.doi.org/10.1128/AAC.50.4.1581-1585.2006.
37. Cui L, Tominaga E, Neoh H, Hiramatsu K. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082. http://dx.doi.org/10.1128/AAC.50.3.1079-1082.2006. (Pubitemid 43327815)
38. Bolister N, Basker M, Hodges N, Marriott C. 1991. The diffusion of β-lactam antibiotics through mixed gels of cystic fibrosis-derived mucin and Pseudomonas aeruginosa alginate. J. Antimicrob. Chemother. 27:285-293. http://dx.doi.org/10.1093/jac/27.3.285.